Puigdelloses Montserrat, González-Huárriz Marisol, García-Moure Marc, Martínez-Vélez Naiara, Esparragosa Vázquez Inés, Bruna Jordi, Zandio Beatriz, Agirre Amaia, Marigil Miguel, Petrirena Gregorio, Nuñez-Córdoba Jorge M, Tejada-Solís Sonia, Díez-Valle Ricardo, Gállego-Culleré Jaime, Martínez-Vila Eduardo, Patiño-García Ana, Alonso Marta M, Gállego Pérez-Larraya Jaime
Health Research Institute of Navarra (IDISNA), Pamplona, Spain.
Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Neurooncol Adv. 2020 Jan 31;2(1):vdaa010. doi: 10.1093/noajnl/vdaa010. eCollection 2020 Jan-Dec.
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Circulating biomarkers may assist in the processes of differential diagnosis and response assessment. GBM cells release extracellular vesicles containing a subset of proteins and nucleic acids. We previously demonstrated that exosomes isolated from the serum of GBM patients had an increased expression of compared to healthy subjects. In this exploratory study, we investigated the role of this small noncoding RNA as a diagnostic biomarker for GBM versus other brain lesions with some potential radiological similarities.
We analyzed the expression of in circulating exosomes of GBM patients ( = 18), healthy controls ( = 30), and patients with subacute stroke ( = 30), acute/subacute hemorrhage ( = 30), acute demyelinating lesions ( = 18), brain metastases ( = 21), and primary central nervous system lymphoma (PCNSL; = 12) using digital droplet PCR.
Expression of was significantly higher in GBM patients than in healthy controls ( = .002). levels were also significantly higher in exosomes from GBM patients than from patients with non-neoplastic lesions (stroke [ = .05], hemorrhage [ = .01], demyelinating lesions [ = .019]) and PCNSL ( = .004). In contrast, no significant differences were found between patients with GBM and brain metastases ( = .573). Receiver operator characteristic curve analyses supported the role of this biomarker in differentiating GBM from subacute stroke, acute/subacute hemorrhage, acute demyelinating lesions, and PCNSL ( < .05), but again not from brain metastases ( = .575).
Our data suggest that the expression of in circulating exosomes could be useful for the differentiation of GBM from non-neoplastic brain lesions and PCNSL, but not from brain metastases.
胶质母细胞瘤（GBM）是成人中最常见的原发性恶性脑肿瘤。循环生物标志物可能有助于鉴别诊断和反应评估过程。GBM细胞释放含有蛋白质和核酸子集的细胞外囊泡。我们之前证明，与健康受试者相比，从GBM患者血清中分离出的外泌体中 的表达增加。在这项探索性研究中，我们研究了这种小非编码RNA作为GBM与其他具有一些潜在放射学相似性的脑病变的诊断生物标志物的作用。
我们使用数字液滴PCR分析了GBM患者（n = 18）、健康对照者（n = 30）、亚急性中风患者（n = 30）、急性/亚急性出血患者（n = 30）、急性脱髓鞘病变患者（n = 18）、脑转移瘤患者（n = 21）和原发性中枢神经系统淋巴瘤（PCNSL；n = 12）循环外泌体中 的表达。
GBM患者中 的表达显著高于健康对照者（P = .002）。GBM患者外泌体中的 水平也显著高于非肿瘤性病变患者（中风[P = .05]、出血[P = .01]、脱髓鞘病变[P = .019]）和PCNSL患者（P = .004）。相比之下，GBM患者与脑转移瘤患者之间未发现显著差异（P = .573）。受试者操作特征曲线分析支持该生物标志物在区分GBM与亚急性中风、急性/亚急性出血、急性脱髓鞘病变和PCNSL方面的作用（P < .05），但同样不能区分GBM与脑转移瘤（P = .575）。
我们的数据表明，循环外泌体中 的表达可用于将GBM与非肿瘤性脑病变和PCNSL区分开来，但不能用于与脑转移瘤的区分。
